StockIQpro
NASDAQ:AXSM

Axsome Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Axsome Therapeutics, Inc.'s revenue grew 65.5% in fiscal 2025 to $638.5M while operating margin rose to −26.1%, its highest in 3 years. Free cash flow was −$93.9M, −14.7% of revenue, and the diluted share count rose 3.8%.Summary generated from Axsome Therapeutics, Inc.'s SEC filings. Latest annual report filed Feb 23, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$638.5M
Revenue growth+65.5%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−26.1%
Net margin−28.7%
ROICn/a
Return on equity−252.1%
Debt / equity2.13
Free cash flow−$93.9M
FCF margin−14.7%
Share count change+3.8%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/a0271386638
Operating income−125−180−232−281−167
Net income−130−187−239−287−183
Free cash flow−109−117−146−129−94

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations